Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O
InChI
InChIKey=QIVBCDIJIAJPQS-VIFPVBQESA-N
InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
Molecular Formula | C11H12N2O2 |
Molecular Weight | 204.2252 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: https://www.drugbank.ca/drugs/DB00150Curator's Comment: description was created based on several sources, including
https://www.drugs.com/tryptophan.html
Sources: https://www.drugbank.ca/drugs/DB00150
Curator's Comment: description was created based on several sources, including
https://www.drugs.com/tryptophan.html
Tryptophan is alpha-aminoacid that is used in the biosynthesis of proteins. It is essential aminoacid in humans, meaning the body cannot synthesize and it must be obtained from the diet. Tryptophan is a precursor of serotonin, and as such is sold over the counter in many countries as a dietary supplement for use as an antidepressant, anxiolytic and sleep aid, however application of tryptophan in these indications is not approved by FDA.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/1704290
Curator's Comment: Tryptophan is utilized by the brain where it is converted to neuromediator serotonin.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/16992614
Curator's Comment: The isolation of tryptophan was first reported by Frederick Hopkins in 1901 through hydrolysis of casein
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: map04726 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2271952 |
|||
Target ID: map00380 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2271952 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | OPTIMAX Approved UseOptimax capsules are used only in combination with other anti-depressants when these anti-depressants have been used alone in a patient for a period of time but have not been sufficiently effective. Launch Date2014 |
|||
Primary | OPTIMAX Approved UseOptimax 500 ing capsules contain L-tryptophan winch is found naturally in animal and plant proteins. L-tryptophan is considered an essential amino acid because our bodies can't make it. It is important for the development and functioning of many organs in the body. After absorbing L-tryptophan from food, our bodies convert it to 5-HTP (5-liydroxytryptophan) and then to serotonin which reduces feelings of anxiety and depression. Launch Date2014 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
717 μM EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6210561/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRYPTOPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2538 μM × h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6210561/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRYPTOPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6210561/ |
100 mg/kg single, oral dose: 100 mg/kg route of administration: Oral experiment type: SINGLE co-administered: |
TRYPTOPHAN plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
10 g single, intravenous Highest studied dose |
healthy, 18-40 years |
|
1800 mg 1 times / day multiple, oral (mean) Dose: 1800 mg, 1 times / day Route: oral Route: multiple Dose: 1800 mg, 1 times / day Sources: |
healthy, 52 years n = 7 Health Status: healthy Age Group: 52 years Sex: F Population Size: 7 Sources: |
Disc. AE: Eosinophilia myalgia syndrome... AEs leading to discontinuation/dose reduction: Eosinophilia myalgia syndrome (7 patients) Sources: |
1.5 g 2 times / day multiple, oral (median) Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: |
unhealthy, adult |
Disc. AE: Eosinophilia myalgia syndrome... AEs leading to discontinuation/dose reduction: Eosinophilia myalgia syndrome Sources: |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Eosinophilia myalgia syndrome | 7 patients Disc. AE |
1800 mg 1 times / day multiple, oral (mean) Dose: 1800 mg, 1 times / day Route: oral Route: multiple Dose: 1800 mg, 1 times / day Sources: |
healthy, 52 years n = 7 Health Status: healthy Age Group: 52 years Sex: F Population Size: 7 Sources: |
Eosinophilia myalgia syndrome | Disc. AE | 1.5 g 2 times / day multiple, oral (median) Dose: 1.5 g, 2 times / day Route: oral Route: multiple Dose: 1.5 g, 2 times / day Sources: |
unhealthy, adult |
PubMed
Title | Date | PubMed |
---|---|---|
Two novel mutations (Y141H; C214Y) and previously published mutation (R142W) in the RDS-peripherin gene in autosomal dominant macular dystrophies in Spanish families. | 2001 |
|
Peripheral interleukin-6 administration increases extracellular concentrations of serotonin and the evoked release of serotonin in the rat striatum. | 2001 Apr |
|
Influence of solvents and leucine configuration at position 5 on tryptophan fluorescence in cyclic enkephalin analogues. | 2001 Apr 5 |
|
IL-4 and IL-13 regulate the induction of indoleamine 2,3-dioxygenase activity and the control of Toxoplasma gondii replication in human fibroblasts activated with IFN-gamma. | 2001 Feb |
|
Pumping capacity of bacterial reaction centers and backpressure regulation of energy transduction. | 2001 Feb |
|
The mood-lowering effect of tryptophan depletion: possible explanation for discrepant findings. | 2001 Feb |
|
Effect of hypothyroidism on pathways for iodothyronine and tryptophan uptake into rat adipocytes. | 2001 Feb |
|
Evidence for a serotonin transporter deficit in experimental acute liver failure. | 2001 Feb |
|
Excessive activation of serotonin (5-HT) 1B receptors disrupts the formation of sensory maps in monoamine oxidase a and 5-ht transporter knock-out mice. | 2001 Feb 1 |
|
Hypochlorous acid damages erythrocyte membrane proteins and alters lipid bilayer structure and fluidity. | 2001 Feb 15 |
|
Tryptophan glycoconjugate as a novel marker of renal function. | 2001 Feb 15 |
|
Tryptophan 95, an amino acid residue of the Caprine arthritis encephalitis virus vif protein which is essential for virus replication. | 2001 Feb 15 |
|
Tryptophan- and dileucine-based endocytosis signals in the neonatal Fc receptor. | 2001 Feb 16 |
|
An activation switch in the ligand binding pocket of the C5a receptor. | 2001 Feb 2 |
|
Extracellular amino acid profiles in the paraventricular nucleus of the rat hypothalamus are influenced by diet composition. | 2001 Feb 23 |
|
N-methyltryptophan oxidase from Escherichia coli: reaction kinetics with N-methyl amino acid and carbinolamine substrates. | 2001 Feb 6 |
|
Monoamine compounds in cerebrospinal fluid of healthy subjects punctured without preceding strict bed rest: a pilot study. | 2001 Jan |
|
No association between tryptophan hydroxylase gene polymorphism and Alzheimer's disease. | 2001 Jan |
|
Quantifying nutrient production by the microbial symbionts in an aphid. | 2001 Jan |
|
Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. | 2001 Jan |
|
Physical exercise and normobaric hypoxia: independent modulators of peripheral cholecystokinin metabolism in man. | 2001 Jan |
|
Membrane fusion by an RGD-containing sequence from the core protein VP3 of hepatitis A virus and the RGA-analogue: implications for viral infection. | 2001 Jan |
|
Metal-catalyzed oxidation of human growth hormone: modulation by solvent-induced changes of protein conformation. | 2001 Jan |
|
Analysis of the subsite specificity of rat insulysin using fluorogenic peptide substrates. | 2001 Jan 12 |
|
Oxidation of human lens recombinant alphaA-crystallin and cysteine-deficient mutants. | 2001 Jan 26 |
|
Crystal structures of pristine and oxidatively processed lignin peroxidase expressed in Escherichia coli and of the W171F variant that eliminates the redox active tryptophan 171. Implications for the reaction mechanism. | 2001 Jan 26 |
|
Contributions of Torpedo nicotinic acetylcholine receptor gamma Trp-55 and delta Trp-57 to agonist and competitive antagonist function. | 2001 Jan 26 |
|
Paramecium calmodulin mutants defective in ion channel regulation associate with melittin in the absence of calcium but require it for tertiary collapse. | 2001 Jan 30 |
|
Low pH-induced conformational changes in vesicular stomatitis virus glycoprotein involve dramatic structure reorganization. | 2001 Jan 5 |
|
Distributions of intramolecular distances in the reduced and denatured states of bovine pancreatic ribonuclease A. Folding initiation structures in the C-terminal portions of the reduced protein. | 2001 Jan 9 |
|
Contryphans from Conus textile venom ducts. | 2001 Jun |
|
A nonsense mutation in the NDUFS4 gene encoding the 18 kDa (AQDQ) subunit of complex I abolishes assembly and activity of the complex in a patient with Leigh-like syndrome. | 2001 Mar 1 |
|
Phage display-selected sequences of the heavy-chain CDR3 loop of the anti-digoxin antibody 26-10 define a high affinity binding site for position 16-substituted analogs of digoxin. | 2001 Mar 16 |
|
C-mannosylation and O-fucosylation of the thrombospondin type 1 module. | 2001 Mar 2 |
|
The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. | 2001 Mar 23 |
Patents
Sample Use Guides
As a dietary supplement, tryptophan is administered orally with tryptophan-reach food (turkey, eggs, beans) or as dietary supplements in the form of tablets.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2271952
Tryptophan hydroxylase activity was assayed in a low-speed supernatant fraction of cerebral cortex or midbrain from a single rat. The enzyme preparation contained 2 mM dithiothreitol and had been subjected to gel filtration to remove small molecules. The assay was carried out in the presence of 200 uM L-tryptophan and 50 gM DL-6-methyl-5,6,7,8-tetrahydropterin.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:03:31 GMT 2023
by
admin
on
Fri Dec 15 16:03:31 GMT 2023
|
Record UNII |
8DUH1N11BX
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
25546-3
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
34384-8
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
3072-6
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
3071-8
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
17752-7
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
53159-0
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
28608-8
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
20659-9
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
15130-8
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
26602-3
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
56993-9
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
3070-0
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
15145-6
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
WHO-ATC |
N06AX02
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
9325-2
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
FDA ORPHAN DRUG |
796220
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
44414-1
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
27334-2
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
32275-0
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
13418-9
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
27135-3
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
3068-4
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
25139-7
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
3069-2
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
25994-5
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
DSLD |
199 (Number of products:65)
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
CFR |
21 CFR 172.320
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
24457-4
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
DSLD |
2783 (Number of products:447)
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
13817-2
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
WHO-VATC |
QN06AX02
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
||
|
LOINC |
74767-5
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
73-22-3
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
29954
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
SUB15631MIG
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
57912
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
8DUH1N11BX
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
10898
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | RxNorm | ||
|
200-795-6
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
6173
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
CHEMBL54976
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
16828
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
C29603
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
8DUH1N11BX
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
4142
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
13119
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
DB00150
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
57719
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
1700501
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
DTXSID5021419
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
D014364
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
2780
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
TRYPTOPHAN
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
m11247
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | Merck Index | ||
|
100000091926
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
27897
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
6305
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY | |||
|
SUB12377MIG
Created by
admin on Fri Dec 15 16:03:31 GMT 2023 , Edited by admin on Fri Dec 15 16:03:31 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
RADIOLIGAND->TARGET |
Used to monitor tryptophan uptake and metabolism
|
||
|
METABOLIC ENZYME -> INDUCER |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE TOXIC -> PARENT |
Metabolised to indole by gut lactobacilli then to indoxyl sulfate in the liver by cypE1 and a sulfation enzyme.
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Formed from tryptophanase from gut bacteria.
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
Metabolized from indole in the liver.
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE -> PARENT |
|
||
|
METABOLITE ACTIVE -> PARENT |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
EP
|
||
|
PARENT -> IMPURITY |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
EP
|
||
|
IMPURITY -> PARENT |
EP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|